University of Califonia, San Francisco
Welcome,         Profile    Billing    Logout  
 9 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Daud, Adil
KEYNOTE-C86, NCT04993677 / 2021-002037-42: A Study of SEA-CD40 Given With Other Drugs in Cancers

Active, not recruiting
2
77
Europe, Canada, US
SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed, Alimta, carboplatin, Paraplatin
Seagen Inc., Merck Sharp & Dohme LLC
Melanoma, Carcinoma, Non-Small- Cell Lung
01/24
10/25
NCT05060003: Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection

Terminated
2
7
US
Atezolizumab, Tecentriq, Tiragolumab, Signatera Assay
Washington University School of Medicine, Genentech, Inc.
Stage II Melanoma
11/23
11/23
OMNIA-1, NCT05578872 / 2021-006711-29: A Study of ANV419 Alone or in Combination with Approved Treatment in Patients with Cutaneous Melanoma ().

Completed
1/2
29
Europe, US
ANV419, Pembrolizumab, Ipilimumab
Anaveon AG, Anaveon AG
Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor, Metastatic Melanoma
08/24
08/24
SGNBB228-001, NCT05571839: A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Recruiting
1
275
Europe, Canada, US
PF-08046049
Seagen Inc.
Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma
11/26
11/27
NCT05695898: XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy

Active, not recruiting
1
6
US
XmAb22841, CTLA-4 X LAG3, Bavunalimab, XmAb23104, PD1 X ICOS, XmAb104
University of California, San Francisco, Xencor, Inc.
Metastatic Melanoma, Advanced Melanoma
12/25
12/25
NCT05105100: Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma

Recruiting
N/A
25
US
Biopsy, Excisional Biopsy, Biospecimen Collection, Specimen Collection
University of California, San Francisco, Merck Sharp & Dohme LLC
Melanoma, Advanced Melanoma
08/26
08/26
Liu, Kathleen D
I-SPY_COVID, NCT04488081: I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Recruiting
2
1500
US
Remdesivir, GS-5734, Imatinib Mesylate, Dexamethasone, Cenicriviroc, Icatibant, Firazyr, Apremilast, Otezla, dornase alfa, Pulmozyme, Celecoxib, celebrex, Famotidine, Pepcid, IC14, Aviptadil, Zyesami, narsoplimab, OMS721, Cyproheptadine, periactin, Cyclosporine, CsA
QuantumLeap Healthcare Collaborative, University of California, San Francisco, University of Pennsylvania, Emory University, University of Alabama at Birmingham, University of Colorado, Denver, University of Southern California, Yale University, Wake Forest University Health Sciences, Sanford Health, Long Beach Memorial Medical Center, Georgetown University, University of California, Davis, Hoag Memorial Hospital Presbyterian, Main Line Health, DHR Health Institute for Research and Development, University of California, Irvine, Corewell Health, Kaiser Permanente, University of Michigan, West Virginia University, University of Miami, University Hospitals Cleveland Medical Center, Virtua Health, M.D. Anderson Cancer Center
COVID-19
07/28
07/30
NCT06654193: Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury

Not yet recruiting
1/2
70
US
Allogeneic HB-adMSCs, Normal Saline
Hope Biosciences, The University of Texas Health Science Center, Houston, University of California, San Francisco, University of Alabama at Birmingham
Acute Kidney Injury
01/28
01/28
LIBERATE-D, NCT04218370: Liberation From Acute Dialysis

Recruiting
N/A
220
US
Dialysis
University of California, San Francisco, Vanderbilt University Medical Center, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Acute Kidney Injury, Kidney; Disease, Acute, Dialysis Related Complication
03/25
06/25
Hsu, Chi-yuan
LIBERATE-D, NCT04218370: Liberation From Acute Dialysis

Recruiting
N/A
220
US
Dialysis
University of California, San Francisco, Vanderbilt University Medical Center, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Acute Kidney Injury, Kidney; Disease, Acute, Dialysis Related Complication
03/25
06/25
APOLLO, NCT03615235: APOL1 Long-term Kidney Transplantation Outcomes Network

Recruiting
N/A
5000
US
Wake Forest University Health Sciences, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Diseases, Kidney Failure, Kidney Disease, Chronic
09/24
09/24
Home-BP, NCT05159999: The Home Blood Pressure (BP) Trial

Recruiting
N/A
200
US
Dry weight target adjustment, Anti-hypertensive medications
University of Washington, University of California, San Francisco, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
End Stage Renal Disease on Dialysis
04/26
04/26

Download Options